Peter has over twenty years’ experience in working in the R&D of the international pharmaceutical companies MSD/Organon, Khondrion and Aduro Biotech Europe, The Netherlands. At Aduro, a company advancing novel antibody therapies for immune-oncology Peter served as the Bioanalytical Lead and contributed extensively in the development of two clinical and one pre-clinical stage antibodies APRIL (BION-1301), CTLA-4 (ADU-1604) and SIRP (ADU-1805), respectively.
Peter’s contribution at Khondrion in the development of unique live-cell imaging patient derived bioassays led to the selection of clinical candidate KH176 (Sonlicromanol), which was granted an orphan drug designation by EMA/FDA and entered Phase IIb KHENERGYZE study to treat a range of mitochondrial diseases. At MSD/Organon, where he headed the cell-based bioanalytical group, he gained a lot of expertise in the performance of bioanalysis of samples from (pre)clinical trials up to Phase III with investigational biological pharmaceuticals in compliance to GLP, which resulted in the launch of Elonva®.
Prior to joining MSD/Organon, Peter worked at the Wageningen University Research Centre and at the Department of Human Genetics at the Radboud University Medical Centre Nijmegen, respectively. At Nijmegen he contributed substantially to the founding of the Nijmegen DNA diagnostic services.